바이오헤븐 파마슈티컬 홀딩 컴퍼니(BHVN)는 NYSE에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $13.83 (-0.43%), 시가총액 $1.28B, 52주 최저~최고 $7.79 ~ $18.11.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorde
바이오헤븐 파마슈티컬 홀딩 컴퍼니의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이오헤븐 파마슈티컬 홀딩 컴퍼니의 현재 주가는 $13.83 (-0.43%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오헤븐 파마슈티컬 홀딩 컴퍼니의 시가총액은 약 $1.28B입니다.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develo